Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13
Phase 21

Trial Status

Completed2
Recruiting2

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT07783477Phase 1Recruiting
A Study of Armored CAR T Cells in People With Cancer
Neuroendocrine CancerSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )
PrincipalinvestigatorStart date: 2026-08-28
NCT07638371Phase 1Recruiting
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Advanced Solid TumorMetastatic Solid TumorSolid Carcinoma+2 more
PrincipalinvestigatorStart date: 2026-06-09
NCT06863233Phase 1Completed
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Lung CancerMetastatic Non Small Cell Lung CancerNon Small Cell Lung Cancer
PrincipalinvestigatorStart date: 2025-03-03
NCT02350764Phase 2Completed
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
Advanced Stage Non-small Cell Lung Cancer
PrincipalinvestigatorStart date: 2015-01-20

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jason Wu

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Related
31 trials

Shared therapeutic areas:

Advanced Solid TumorSmall Cell Lung CarcinomaSolid Tumor+2 more
Similarity Score13%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungLung CancerSmall Cell Lung Carcinoma+1 more
Similarity Score10%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Solid TumorAdvanced Solid TumorCarcinoma, Non-Small-Cell Lung+1 more
Similarity Score10%

Lin Shen, MD

Peking University Cancer Hospital & Institute

Related
20 trials

Shared therapeutic areas:

Solid TumorAdvanced Solid TumorLung Cancer
Similarity Score8%

Yongchang Zhang, MD

Hunan Cancer Hospital

Related
27 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungLung CancerSmall Cell Lung Carcinoma
Similarity Score8%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Lung CancerCarcinoma, Non-Small-Cell LungSolid Tumor
Similarity Score8%

Michael B Gill

Power Life Sciences Inc.

Related
105 trials

Shared therapeutic areas:

Lung CancerCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma
Similarity Score8%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Lung CancerCarcinoma, Non-Small-Cell Lung
Similarity Score5%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungLung Cancer
Similarity Score5%

Project Leader

Ono Pharmaceutical Co., Ltd.

Related
47 trials

Shared therapeutic areas:

Solid TumorCarcinoma, Non-Small-Cell Lung

Worked with same sponsors:

Bristol-Myers Squibb
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT07783477Phase 1PrincipalInvestigator

A Study of Armored CAR T Cells in People With Cancer

Neuroendocrine CancerSmall Cell Lung CancerSmall Cell Lung Cancer ( SCLC )
Recruiting
NCT07638371Phase 1PrincipalInvestigator

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

Advanced Solid TumorMetastatic Solid TumorSolid Carcinoma+2 more
Recruiting
NCT06863233Phase 1PrincipalInvestigator

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Lung CancerMetastatic Non Small Cell Lung CancerNon Small Cell Lung Cancer
Completed
NCT02350764Phase 2PrincipalInvestigator

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Advanced Stage Non-small Cell Lung Cancer
Completed

All 4 trials loaded